Results 31 to 40 of about 4,786 (145)

Varicella-Zoster Virus Reactivation amid the COVID-19 pandemic- Do we need to be vigilant? A mini review [PDF]

open access: yesĶazaķstannyṇ Klinikalyķ Medicinasy, 2020
Reactivation of varicella-zoster infection has been noted in a subset of COVID-19 patients. This has been attributed to immune dysregulation resulting from SARS-CoV-2 infection.
Mishal Shan Siddiqui, Nimra Hasnain
doaj   +1 more source

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. [PDF]

open access: yesPLoS ONE, 2009
BACKGROUND:Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients.
Andre C Kalil   +3 more
doaj   +1 more source

Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin

open access: yesImmunity, Inflammation and Disease, 2021
Objective Cytomegalovirus (CMV) infections are correlated with complications following heart transplantation (HTx) and impaired outcome. The impact of a serologic mismatch between donor and recipient and the necessity of prophylactic virostatic ...
Moritz B. Immohr   +10 more
doaj   +1 more source

In Vitro Treatment with Ganciclovir Restores the Functionality of Exhausted T Cells from Cancer Patients

open access: yesInternational Journal of Gerontology, 2013
Background: Human cytomegalovirus (CMV) is a lifelong, often asymptomatic infection, with the virus maintained in latently infected myeloid cells. Patients receiving chemotherapy for cancer are at high risk of reactivation of latent CMV, which may ...
Chia-Ming Chang   +6 more
doaj   +1 more source

Treatment of gastroparesis with botulinum toxin in patient after allogenic bone marrow transplantation [PDF]

open access: yesТерапевтический архив, 2018
The case report of botulinum toxin treatment of gastroparesis in a patient following allogenic bone marrow transplantation is described. The causes of gastroparesis and methods of prevention and treatment are discussed.
G M Galstyan   +6 more
doaj   +1 more source

Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods

open access: yesClinical Ophthalmology, 2014
Jane Huang,1 Kazuaki Kadonosono,2 Eiichi Uchio1 1Department of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, 2Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Purpose: The most common external ocular
Huang J, Kadonosono K, Uchio E
doaj  

Long-Term Outcome of Treatment with 2% Topical Ganciclovir Solution in Cytomegalovirus Anterior Uveitis and Corneal Endotheliitis

open access: yesInfection and Drug Resistance, 2022
Po-Jui Chen,1 I-Huang Lin,1 Yi-Chun Chi,2 Chun-Chieh Lai,1 Jia-Horung Hung,1 Sung-Huei Tseng,1 Yi-Hsun Huang1 1Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan ...
Chen PJ   +6 more
doaj  

A UHPLC–MS/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots

open access: yesBiomedicines, 2021
The role of therapeutic drug monitoring (TDM) of valaciclovir (VA)/aciclovir (A) and valganciclovir/ganciclovir (VG/G) in critically ill patients is still a matter of debate.
Federica Pigliasco   +8 more
doaj   +1 more source

Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients

open access: yesBMC Ophthalmology, 2018
Background The purpose of this study is to examine the clinical outcomes achieved by using initial high-dose intravitreal ganciclovir injections to treat cytomegalovirus retinitis in patients without human immunodeficiency virus (HIV) infection.
Zhuyun Qian   +3 more
doaj   +1 more source

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir

open access: yesPharmaceutics, 2023
Background: Ganciclovir and valganciclovir are used for prophylaxis and treatment of cytomegalovirus infection. However, there is great interindividual variability in ganciclovir’s pharmacokinetics (PK), highlighting the importance of individualized ...
Wenyu Yang   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy